---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40128955.md"
description: "$XTALPI(02228.HK)AACR2026 disclosure: 1. AI+ Organoid Platform (Signet collaboration)Technology iteration: Second-generation organoid throughput increased 10x, cycle shortened by 50%, cost reduced by 70%; added immune microenvironment co-culture, enabling precise prediction of immunotherapy response.2. Pipeline matrix: Besides SIGX1094R (Claudin18.2, Phase I) and SIGX2649 (TEAD, Q2 IND), the third FIC pipeline (unnamed) has entered the PCC stage, targeting G protein-coupled receptor (GPCR) for pancreatic cancer, with data disclosure expected by the end of 2026.3. Commercial rights: Agreement with Signet stipulates that Jingtai will receive up to 10% royalty after SIGX2649 commercialization; platform technology licensed to 3 pharmaceutical companies, with upfront payment + milestones totaling over USD 100 million."
datetime: "2026-04-23T08:29:33.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40128955.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40128955.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40128955.md)
author: "[wolf-001](https://longbridge.com/en/profiles/15460724.md)"
---

# $XTALPI(02228.HK)AACR2026 disclosure: 1. AI+ Organ…


### Related Stocks

- [02228.HK](https://longbridge.com/en/quote/02228.HK.md)
- [SIG.US](https://longbridge.com/en/quote/SIG.US.md)